FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology, and can be used to correct neurological deficits in traumatic brain injury. A method for correcting neurological deficit in traumatic brain injury involves reproducing traumatic brain injury in male rats weighing 270±20 g. To correct neurological deficit, trimetazidine is administered intragastrically at a dose of 6.6 mg/kg per day, divided into 2 doses with at intervals of 12 hours from 1 to 7 days of the experiment, inclusive. Moreover, trimetazidine begins to be administered 2 hours before the simulation of the experimental traumatic brain injury.
EFFECT: invention provides an effective method for correcting neurological deficits in an experimental model of traumatic brain injury, including the use of trimetazidine.
1 cl, 5 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR CORRECTING NEUROLOGICAL DEFICIENCY OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2758433C1 |
METHOD FOR CORRECTION OF PATHOLOGY OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2766785C1 |
METHOD FOR CORRECTING MORPHOLOGICAL CHANGES IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2758545C1 |
METHOD FOR CORRECTING THE NEUROLOGICAL STATUS WITH 2-ETHYL-6-METHYL-3-HYDROXY PYRIDINIUM-N-ACETYLAMINOACETATE IN CASE OF BRAIN DAMAGE DUE TO INTRACEREBRAL HEMORRHAGE IN THE EXPERIMENT | 2022 |
|
RU2786315C1 |
METHOD FOR CORRECTION OF CEREBRAL ISCHEMIA WITH RAPITALAM SUBSTANCE IN EXPERIMENTS | 2019 |
|
RU2711906C1 |
METHOD FOR PREVENTING CEREBRAL ISCHEMIA | 2018 |
|
RU2696203C1 |
METHOD FOR PREVENTION OF BRAIN ISCHEMIA | 2017 |
|
RU2642961C1 |
METHOD FOR CORRECTING BEHAVIORAL STATUS OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN TRAUMATIC BRAIN INJURY | 2021 |
|
RU2756325C1 |
METHOD FOR CORRECTING THE BEHAVIORAL STATUS OF 2-AMINO-5-ETHYL-1,3,4-THIODIAZOLIUM-N-ACETYL-AMINOETHANOATE IN CASE OF BRAIN DAMAGE | 2021 |
|
RU2763012C1 |
NEURORABILITATION AGENT BASED ON SODIUM 6-OXO-1-PHENYL-2-(PHENYLAMINO)-1,6-DIHYDROPYRIMIDINE-4-OLATE | 2018 |
|
RU2675694C1 |
Authors
Dates
2021-10-27—Published
2021-03-29—Filed